BOOST Pharma to Present BT-101 Update at Cell & Gene Meeting on the Mesa

BOOST Pharma, a clinical-stage biopharmaceutical company developing novel, first-in-class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, has been selected as a 2026 Innovation Spotlight company at the upcoming Cell & Gene Meeting on the Mesa, taking place in Phoenix, Arizona, from 5-7 October 2026.

The company's Chief Executive Officer, Hans Schambye, will present an update on BT-101, the Phase III-ready investigational, off-the-shelf allogeneic stem cell therapy for children with severe osteogenesis imperfecta (OI), also known as brittle bone disease. The presentation will highlight BT-101's clinical development progress, encouraging clinical data, and preparations for a planned pivotal Phase III study.

Osteogenesis imperfecta affects an estimated 1 in 15,000 people globally. Children with severe forms of the disease may experience dozens to hundreds of fractures throughout their lifetime and often face significant skeletal deformities, reduced mobility, respiratory complications, hearing loss, and diminished quality of life. Despite the substantial burden of disease, there are currently no FDA- or EMA-approved therapies for OI.

BT-101 is designed for early intervention, with the potential to address defective bone formation before fractures and skeletal deformities progress. As an off-the-shelf therapy, it requires no patient matching, conditioning, or pretreatment. In the BOOSTB4 Study, a Phase I/II clinical trial, BT-101 was generally well tolerated and associated with an approximately 70% reduction in fracture rates in young children with severe OI, supporting its advancement toward a planned pivotal Phase III study.

Hans Schambye, CEO of BOOST Pharma, expressed his excitement about the company's recognition and the upcoming presentation.

The presentation is scheduled for Tuesday, 6 October 2026, at 11:00 a.m. MST in the FLW Ballroom G at the Arizona Biltmore Hotel. Ahead of the Cell & Gene Meeting on the Mesa, Schambye will also attend the Alliance for Regenerative Medicine CEO Summit in Phoenix on October 4, 2026, where he will meet with investors and potential partners.